Lyka Labs Quarterly Results for Trading Insights
In Mar 2026, Lyka Labs (LYKALABS) reported revenue ₹29 Cr and net profit ₹-8 Cr — revenue -14.7% YoY. For annual financials, live price and key ratios, visit Lyka Labs stock price NSE.
LYKALABS Quarterly Results — Revenue, Profit & EPS Highlights
Lyka Labs latest quarter revenue, net profit, EPS and QoQ/YoY growth rates. Also explore LYKALABS price trends to track price trends across different timeframes.
- Revenue of ₹29 Cr in Mar 2026 (-23.7% vs Sept 2025, -14.7% vs Mar 2025)
- Net Profit of ₹-8 Cr in Mar 2026 (-166.7% vs Sept 2025, -500.0% vs Mar 2025)
- EBITDA of ₹-6 Cr in Mar 2026 (-200.0% vs Sept 2025)
- Operating Margin of -23.0% in Mar 2026 (-16.0pp vs Sept 2025)
- Earnings Per Share of ₹-2.13 in Mar 2026 (-126.6% vs Sept 2025)
Lyka Labs Quarterly Results — Revenue, EBITDA, Net Profit & EPS
LYKALABS quarterly revenue, expenses, EBITDA, net profit, EPS and operating margin with QoQ and YoY comparison.
| Metric | Mar 2026 | Sept 2025 | Mar 2025 | Jun 2025 | Dec 2025 | QoQ | YoY |
|---|---|---|---|---|---|---|---|
| Revenue (₹ Cr) | 29 | 38 | 34 | 34 | 32 | -23.7% | -14.7% |
| Net Profit (₹ Cr) | -8 | -3 | 2 | 1 | 0 | - | - |
| EBITDA (₹ Cr) | -6 | -2 | 5 | 4 | 3 | - | - |
| EPS (₹) | -2.13 | -0.94 | 0.49 | 0.25 | 0.00 | - | - |
| Operating Margin (%) | -23.0% | -7.0% | 12.0% | 11.0% | 5.0% | - | - |
LYKALABS Share Price Trend — 1-Year Movement Across Quarterly Results
Lyka Labs 1-year share price in ₹ overlaid with quarterly earnings dates — NSE/BSE closing prices. Browse LYKALABS complete financial statements for revenue, profit, balance sheet and cash flow data.
Revenue Trend (₹ Cr)
Net Profit Trend (₹ Cr)
Operating Margin Trend (%)
LYKALABS vs Healthcare Peers — Quarterly Revenue, Profit & Market Cap
Lyka Labs latest quarter revenue and net profit vs Healthcare competitors — market cap, price and earnings comparison.
| Company Latest Quarter | Market Cap (₹ Cr) | Price (₹) | Revenue (₹ Cr) | Net Profit (₹ Cr) | Rev QoQ % | Rev YoY % | Profit Margin % | P/E Ratio |
|---|---|---|---|---|---|---|---|---|
|
Sun Pharmaceutical
Mar 2026 |
₹454,122.13 Cr | 1904.8 | 15,018 | 2,710 | +1.0% | +11.8% | 18.0% | 168.6 |
|
Divis Laboratories
Mar 2026 |
₹174,081.02 Cr | 6757.0 | 2,986 | 751 | +4.4% | +11.8% | 25.2% | 238.7 |
|
Torrent Pharmaceuti…
Mar 2026 |
₹161,380.94 Cr | 4768.3 | 4,111 | 364 | +27.7% | +42.2% | 8.9% | 414.3 |
|
Cipla
Mar 2026 |
₹117,800.00 Cr | 1458.2 | 6,612 | 543 | -14.3% | -4.0% | 8.2% | 212.3 |
|
Dr Reddys Laborator…
Mar 2026 |
₹114,691.88 Cr | 1374.1 | 7,996 | 221 | -12.5% | -11.5% | 2.8% | 518.5 |
All amounts in ₹ Crores